BHVN Stock Recent News
BHVN LATEST HEADLINES
Here is how Biohaven Ltd. (BHVN) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Biohaven Ltd. (BHVN) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
"We can now say you know that Nurtec ODT is approved for the preventative treatment of migraine," Biohaven CEO Vlad Coric said.
Biohaven Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume.
Biohaven's most valuable migraine-related assets were recently acquired by Pfizer for $11.6 billion. This has left a far smaller stub of cash and other pharmaceutical assets now trading as Biohaven that may be worth around $24/share, well above the current price.
The newly spun-off Biohaven Ltd. (BHVN) advances a portfolio of non-CGRP pipelines targeting neurological and neuropsychiatric indications.
The "new" Biohaven is enjoying plenty of attention from investors.
Cramer spoke with Biohaven CEO Vlad Coric on Tuesday.
The "old" Biohaven is gone, leaving the "new" Biohaven to rise.
Biohaven Pharmaceuticals (BHVN) suffers a setback as verdiperstat fails to meet the primary and secondary endpoints in an ALS study.